Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in North America, today announced the presentation of new efficacy and benefit-risk assessment data for MAVENCLAD™ (Cladribine Tablets) at the 4th Congress of the European Association of Neurology (EAN)
June 18, 2018
· 6 min read